PDCD1 and non-small cell lung carcinoma: A study using the subcutaneous administration of 5 mg, once for 2 weeks followed by intratumoral injections once weekly for 3 weeks followed by every 3 weeks thereafter, in combination with atezolizumab in 29 patients with NSCLC who had progressed s following PD-1 treatment was stopped due to lack of response66.